HSINCHU, Taiwan, June 08, 2018 (GLOBE NEWSWIRE) -- Taiwan's Hsinchu Biomedical Science Park continues to gain momentum and companies that have entered the park are gathering steam. Led by the Hsinchu Science Park, a number of firms in the biomedical park are participating in a delegation visiting the United States in an effort to expand their visibility in the marketplace and gain footholds in international markets.
Representatives from EIRGENIX, PharmaEssentia, Mycenax Biotech Inc., Andros Pharmaceuticals Co., Ltd, TaiwanJ, and WeMed Biotech are joining the delegation. EIRGENIX has developed EG12014, which is a new drug to treat breast cancer and stomach cancer. Meanwhile, PharmaEssentia's new drug P1101 (Ropeg) can significantly reduce side effects when it is used in the treatment of erythropoiesis, while raising safety and providing the flexibility for large adjustments in dosages. Mycenax Biotech Inc has developed a rheumatoid arthritis medication called LusiNEX that entered Stage 1 clinical trials in Australia last year. The drug also passed a human clinical trial review by the UK's MHRA this year. The herpes zoster neuralgia spray developed by Andros Pharmaceuticals Co., Ltd. has obtained approval from the US FDA to begin clinical trials and in the future could offer a solution to patients with herpes zoster neuralgia. Lastly, TaiwanJ's new drug JKB-122 that treats autoimmune hepatitis is entering Stage 2 clinical trials.
The Hsinchu Biomedical Science Park acts as a powerhouse of the cultivating innovation and biomedical industrialization. In addition to general services and infrastructure, the Park also provides business planning, instructional research, clinical tests, research and clinical trial-related hardware facilities, human resource, business and legal affairs-related services and investment services. The Park can significantly reduce R&D cost, increase success rate of biotechnology corporations, and ensure formation of biomedical industry in Taiwan via the business platform, integrated resources, and clinical trial-related facilities.
The Hsinchu Science Park Bureau stated that Taiwan's biotech industry continues to gain energy thanks to support from the government. The Hsinchu Biomedical Science Park is already involved in late stage clinical trials with a variety of new drugs. In addition, companies situated in the park are increasingly moving upstream and engaging in their own R&D rather than serving as purely contract manufacturing organizations (CMOs). These firms are providing clients, many of which are international pharmaceutical heavyweights, with contract development and manufacturing organization (CDMO) services, ranging from clinical drug R&D to commercialization, thereby seizing a greater slice of business in the sector. We will assist our global partners to expand the market productivity, strengthening the efforts in collaboration.
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/Attachm...e4ff3684bc
